This inventor holds 4 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Ono Pharmaceutical Co., Ltd.. Active years: 2008-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Mishima-gun, JP (2008 - 2011)
- Osaka, JP (2020 - 2022)
Company Filing History:
Years Active: 2008-2022
Title: Seishi Katsumata: Innovator in Medical Biomarkers and Therapeutics
Introduction
Seishi Katsumata is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of medical research, particularly in the development of biomarkers and therapeutic agents. With a total of 4 patents to his name, Katsumata's work is paving the way for advancements in the diagnosis and treatment of various medical conditions.
Latest Patents
One of Katsumata's latest patents focuses on a biomarker for the diagnosis of irritable bowel syndrome (IBS). This innovative biomarker is a metabolite found in biological samples that can be collected through noninvasive methods. It allows for convenient analysis and varies according to the progression of pathological conditions of IBS. This biomarker is instrumental in determining the presence or absence of morbidity, the severity of IBS, the types of IBS, the necessity of treatment, and the confirmation of drug efficacy for IBS therapeutic agents.
Another significant patent by Katsumata is for a prophylactic and/or therapeutic agent for fibromyalgia. The compound, (1S)-2-acetyl-1-(4-chloro-2-methoxyphenyl)-5-fluoro-1,2,3,9-tetrahydrospiro[β-carboline-4,1'-cyclopropane], has shown promising results in significantly suppressing the decrease of pain threshold compared to well-known TSPO antagonists. This makes it an excellent candidate for treating fibromyalgia and its associated symptoms.
Career Highlights
Seishi Katsumata is currently associated with Ono Pharmaceutical Co., Ltd., where he continues to innovate and contribute to the field of pharmaceuticals. His work is characterized by a strong focus on improving patient outcomes through the development of effective diagnostic and therapeutic solutions.
Collaborations
Katsumata has collaborated with notable colleagues, including Kazuyuki Ohmoto and Masashi Kato. These partnerships have further enhanced his research and development efforts, leading to impactful innovations in the medical field.
Conclusion
Seishi Katsumata's contributions to medical research through his patents and collaborations highlight his role as a key innovator in the field. His work on biomarkers and therapeutic agents is set to make a significant impact on the diagnosis and treatment of conditions like irritable bowel syndrome and fibromyalgia
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile